![1]()
News
C. difficile guidelines offer new possibilities
June 24, 2021
Updated recommendations address issues of diagnosis, recurrence, and fecal microbial transplant.
![1]()
News
FDA to add myocarditis warning to mRNA COVID-19 vaccines
June 24, 2021
But a CDC advisory panel, where the FDA made the announcement, still strongly backs the vaccines’ benefits, which outweigh the rare risk for heart inflammation.
![1]()
News
Tofacitinib shows mortality benefit in patients with COVID-19 pneumonia
June 23, 2021
The Janus kinase inhibitor tofacitinib reduces the risk of both death and respiratory failure in hospitalized adults with COVID-19 pneumonia.
![1]()
News
Sotagliflozin use in T2D patients linked with posthospitalization benefits in analysis
June 23, 2021
The paper’s outcome measure may be a meaningful, patient-centered way of capturing disease burden, according to the authors.
News
New data on COVID-19’s cognitive fallout
June 22, 2021
“Low levels of oxygen in the brain could lead to confusion, headache, and brain fog, and cause the cognitive disturbances that we see.”
![1]()
News
Fact or fiction? Intravascular contrast and acute kidney injury
June 22, 2021
The risks of contrast-associated AKI are overstated, implying the truer danger lies with inadequate imaging.
![1]()
News
Safety-net burden linked with poorer inpatient cirrhosis outcomes
June 21, 2021
Even so, hospitalizations and mortality were still higher in Black patients than White patients after controlling for hospitals’ safety-net burden.
News
Prophylactic anticoagulation tied to lower death rate in COVID
June 18, 2021
Prophylactic use of low-dose anticoagulation to prevent venous thromboembolism was associated with reduced 60-day mortality in patients hospitalized with COVID-19 in Michigan.
News
U.S., international MIS-C studies yield disparate results
June 18, 2021
The two real-world observational studies were published online in The New England Journal of Medicine.
News
Reversal agents curb DOAC-related bleeding but deaths still high
June 17, 2021
The meta-analysis of more than 4,000 patients also showed thrombotic events were more frequent with andexanet than with 4PCC or idarucizumab.
